Sphere Medical Holding plc Update on financing and operations (0582L)
14 Julio 2017 - 1:00AM
UK Regulatory
TIDMSPHR
RNS Number : 0582L
Sphere Medical Holding plc
14 July 2017
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.
Cambridge, UK - 14 July 2017
Sphere Medical Holding plc
("Sphere", "Sphere Medical" or the "Company")
Update on financing and operations
Financing and working capital
As announced in our Preliminary Results on 28 February 2017, the
Board remains committed to the Proxima platform and is exploring
its immediate financing options to ensure the Company has
sufficient working capital to realise the full potential of Proxima
and to maximise value for shareholders.
Having undertaken market soundings with existing shareholders
and potential new investors, interest exists from a number of
parties in participating in an equity fundraising, the details of
which are being discussed. The Board remains focussed on the
immediate financing options for the Company to secure its short and
medium term working capital requirements.
Further announcements will be made in due course.
Operational update and prospects
Since the launch of Proxima 4 in December 2016 there has been a
positive reaction in the market and the sales pipeline has
continued to expand. The sales cycle is expected to be typically
around nine months or longer. By 30 June 2017, 55 hospital
departments engaged with Sphere Medical on Proxima 4 and requested
evaluations, of which 38 so far have received a product
demonstration. Furthermore, six customers have already placed
orders within the first six months after launch.
The Board is pleased to report that the main issues surrounding
the limitation on supply of Proxima 4 sensors announced on 2 May
this year have been effectively addressed. Whilst this limitation
constrained sales activity during the first half of this year, the
Board is confident that the current improvement in sensor yields
will ensure sufficient supply to meet demand for the remainder of
the year and beyond.
Our three distributors in continental Europe have all now
received initial supplies of Proxima 4 and have received training.
Patient evaluations have also commenced in all three
territories.
- Ends -
The Market Abuse Regulation ("MAR") became effective from 3 July
2016. Market Soundings, as defined in MAR, were taken in respect of
the proposed Placing with the result that certain persons became
aware of inside information, as permitted by MAR. That inside
information is set out in this announcement and has been disclosed
as soon as possible in accordance with paragraph 7 of article 17 of
MAR. Therefore, those persons that received inside information in a
Market Sounding are no longer in possession of inside information
relating to the Company and its securities.
For further information, please contact:
Sphere Medical Holding plc Tel: +44 (0)1223 875
222
Dr Wolfgang Rencken, Chief
Executive Officer
Richard Wright, Chief Financial
Officer
Panmure Gordon Tel: +44 (0) 20 7886
2500
Freddy Crossley (Corporate
Finance)
Duncan Monteith (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Consilium Strategic Communications Tel: +44 (0) 20 3709
5700
Mary-Jane Elliott spheremedical@consilium-comms.com
Ivar Milligan
Rosie Phillips
Notes for Editors
About Sphere Medical (AIM: SPHR.L)
Sphere Medical is an innovative point-of-care medical device
company. Its Proxima platform measures blood gases, electrolytes
and metabolites at the patient's bedside and aims to improve
patient care and reduce health system costs. The device is sold
directly to the critical care market via Sphere Medical's sales
force in the UK, Germany, The Netherlands and Belgium and via
distributors in Italy, Spain and Austria. For further information,
please visit www.spheremedical.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
UPDSFSEDDFWSELW
(END) Dow Jones Newswires
July 14, 2017 02:00 ET (06:00 GMT)
Sphere Medical (LSE:SPHR)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Sphere Medical (LSE:SPHR)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025